Research ArticleArticle
Endothelial Activation Markers as Disease Activity and Damage Measures in Juvenile Dermatomyositis
Takayuki Kishi, Jonathan Chipman, Melvina Evereklian, Khanh Nghiem, Maryalice Stetler-Stevenson, Margaret E. Rick, Michael Centola, Frederick W. Miller and Lisa G. Rider
The Journal of Rheumatology August 2019, jrheum.181275; DOI: https://doi.org/10.3899/jrheum.181275
Takayuki Kishi
From the Environmental Autoimmunity Group, Clinical Research Branch, US National Institute of Environmental Health Sciences, National Institutes of Health (NIH); Coagulation Laboratory, NIH Clinical Center; Laboratories of Molecular Biology and Pathology, National Cancer Institute, NIH, Bethesda, Maryland; Oklahoma Medical Research Foundation; Haus Bioceuticals Inc., Oklahoma City, Oklahoma, USA. This work was supported in part by the Intramural Research Program of the National Institute of Environmental Health Sciences (project ES101074, Takayuki Kishi, Lisa Rider, and Frederick Miller). Takayuki Kishi was supported by a research fellowship of the Cure JM Foundation and by Tokyo Women’s Medical University. T. Kishi, MD, PhD, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH; J. Chipman, MS, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH; M. Evereklian, MSN, CPNP-BC, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH; K. Nghiem, MS, Coagulation Laboratory, NIH Clinical Center; M. Stetler-Stevenson, MD, Laboratories of Molecular Biology and Pathology, National Cancer Institute, NIH; M.E. Rick, MD, Coagulation Laboratory, NIH Clinical Center; M. Centola, PhD, Oklahoma Medical Research Foundation, and Haus Bioceuticals Inc.; F.W. Miller, MD, PhD, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH; L.G. Rider, MD, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH. Address correspondence to Dr. L.G. Rider, Deputy Chief, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH, Building 10, CRC Rm 6-5700, MSC 1301, 10 Center Drive, Bethesda, Maryland 20892-1301, USA. E-mail: riderl@mail.nih.gov. Accepted for publication July 19, 2019.
Jonathan Chipman
From the Environmental Autoimmunity Group, Clinical Research Branch, US National Institute of Environmental Health Sciences, National Institutes of Health (NIH); Coagulation Laboratory, NIH Clinical Center; Laboratories of Molecular Biology and Pathology, National Cancer Institute, NIH, Bethesda, Maryland; Oklahoma Medical Research Foundation; Haus Bioceuticals Inc., Oklahoma City, Oklahoma, USA. This work was supported in part by the Intramural Research Program of the National Institute of Environmental Health Sciences (project ES101074, Takayuki Kishi, Lisa Rider, and Frederick Miller). Takayuki Kishi was supported by a research fellowship of the Cure JM Foundation and by Tokyo Women’s Medical University. T. Kishi, MD, PhD, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH; J. Chipman, MS, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH; M. Evereklian, MSN, CPNP-BC, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH; K. Nghiem, MS, Coagulation Laboratory, NIH Clinical Center; M. Stetler-Stevenson, MD, Laboratories of Molecular Biology and Pathology, National Cancer Institute, NIH; M.E. Rick, MD, Coagulation Laboratory, NIH Clinical Center; M. Centola, PhD, Oklahoma Medical Research Foundation, and Haus Bioceuticals Inc.; F.W. Miller, MD, PhD, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH; L.G. Rider, MD, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH. Address correspondence to Dr. L.G. Rider, Deputy Chief, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH, Building 10, CRC Rm 6-5700, MSC 1301, 10 Center Drive, Bethesda, Maryland 20892-1301, USA. E-mail: riderl@mail.nih.gov. Accepted for publication July 19, 2019.
Melvina Evereklian
From the Environmental Autoimmunity Group, Clinical Research Branch, US National Institute of Environmental Health Sciences, National Institutes of Health (NIH); Coagulation Laboratory, NIH Clinical Center; Laboratories of Molecular Biology and Pathology, National Cancer Institute, NIH, Bethesda, Maryland; Oklahoma Medical Research Foundation; Haus Bioceuticals Inc., Oklahoma City, Oklahoma, USA. This work was supported in part by the Intramural Research Program of the National Institute of Environmental Health Sciences (project ES101074, Takayuki Kishi, Lisa Rider, and Frederick Miller). Takayuki Kishi was supported by a research fellowship of the Cure JM Foundation and by Tokyo Women’s Medical University. T. Kishi, MD, PhD, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH; J. Chipman, MS, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH; M. Evereklian, MSN, CPNP-BC, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH; K. Nghiem, MS, Coagulation Laboratory, NIH Clinical Center; M. Stetler-Stevenson, MD, Laboratories of Molecular Biology and Pathology, National Cancer Institute, NIH; M.E. Rick, MD, Coagulation Laboratory, NIH Clinical Center; M. Centola, PhD, Oklahoma Medical Research Foundation, and Haus Bioceuticals Inc.; F.W. Miller, MD, PhD, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH; L.G. Rider, MD, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH. Address correspondence to Dr. L.G. Rider, Deputy Chief, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH, Building 10, CRC Rm 6-5700, MSC 1301, 10 Center Drive, Bethesda, Maryland 20892-1301, USA. E-mail: riderl@mail.nih.gov. Accepted for publication July 19, 2019.
Khanh Nghiem
From the Environmental Autoimmunity Group, Clinical Research Branch, US National Institute of Environmental Health Sciences, National Institutes of Health (NIH); Coagulation Laboratory, NIH Clinical Center; Laboratories of Molecular Biology and Pathology, National Cancer Institute, NIH, Bethesda, Maryland; Oklahoma Medical Research Foundation; Haus Bioceuticals Inc., Oklahoma City, Oklahoma, USA. This work was supported in part by the Intramural Research Program of the National Institute of Environmental Health Sciences (project ES101074, Takayuki Kishi, Lisa Rider, and Frederick Miller). Takayuki Kishi was supported by a research fellowship of the Cure JM Foundation and by Tokyo Women’s Medical University. T. Kishi, MD, PhD, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH; J. Chipman, MS, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH; M. Evereklian, MSN, CPNP-BC, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH; K. Nghiem, MS, Coagulation Laboratory, NIH Clinical Center; M. Stetler-Stevenson, MD, Laboratories of Molecular Biology and Pathology, National Cancer Institute, NIH; M.E. Rick, MD, Coagulation Laboratory, NIH Clinical Center; M. Centola, PhD, Oklahoma Medical Research Foundation, and Haus Bioceuticals Inc.; F.W. Miller, MD, PhD, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH; L.G. Rider, MD, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH. Address correspondence to Dr. L.G. Rider, Deputy Chief, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH, Building 10, CRC Rm 6-5700, MSC 1301, 10 Center Drive, Bethesda, Maryland 20892-1301, USA. E-mail: riderl@mail.nih.gov. Accepted for publication July 19, 2019.
Maryalice Stetler-Stevenson
From the Environmental Autoimmunity Group, Clinical Research Branch, US National Institute of Environmental Health Sciences, National Institutes of Health (NIH); Coagulation Laboratory, NIH Clinical Center; Laboratories of Molecular Biology and Pathology, National Cancer Institute, NIH, Bethesda, Maryland; Oklahoma Medical Research Foundation; Haus Bioceuticals Inc., Oklahoma City, Oklahoma, USA. This work was supported in part by the Intramural Research Program of the National Institute of Environmental Health Sciences (project ES101074, Takayuki Kishi, Lisa Rider, and Frederick Miller). Takayuki Kishi was supported by a research fellowship of the Cure JM Foundation and by Tokyo Women’s Medical University. T. Kishi, MD, PhD, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH; J. Chipman, MS, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH; M. Evereklian, MSN, CPNP-BC, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH; K. Nghiem, MS, Coagulation Laboratory, NIH Clinical Center; M. Stetler-Stevenson, MD, Laboratories of Molecular Biology and Pathology, National Cancer Institute, NIH; M.E. Rick, MD, Coagulation Laboratory, NIH Clinical Center; M. Centola, PhD, Oklahoma Medical Research Foundation, and Haus Bioceuticals Inc.; F.W. Miller, MD, PhD, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH; L.G. Rider, MD, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH. Address correspondence to Dr. L.G. Rider, Deputy Chief, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH, Building 10, CRC Rm 6-5700, MSC 1301, 10 Center Drive, Bethesda, Maryland 20892-1301, USA. E-mail: riderl@mail.nih.gov. Accepted for publication July 19, 2019.
Margaret E. Rick
From the Environmental Autoimmunity Group, Clinical Research Branch, US National Institute of Environmental Health Sciences, National Institutes of Health (NIH); Coagulation Laboratory, NIH Clinical Center; Laboratories of Molecular Biology and Pathology, National Cancer Institute, NIH, Bethesda, Maryland; Oklahoma Medical Research Foundation; Haus Bioceuticals Inc., Oklahoma City, Oklahoma, USA. This work was supported in part by the Intramural Research Program of the National Institute of Environmental Health Sciences (project ES101074, Takayuki Kishi, Lisa Rider, and Frederick Miller). Takayuki Kishi was supported by a research fellowship of the Cure JM Foundation and by Tokyo Women’s Medical University. T. Kishi, MD, PhD, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH; J. Chipman, MS, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH; M. Evereklian, MSN, CPNP-BC, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH; K. Nghiem, MS, Coagulation Laboratory, NIH Clinical Center; M. Stetler-Stevenson, MD, Laboratories of Molecular Biology and Pathology, National Cancer Institute, NIH; M.E. Rick, MD, Coagulation Laboratory, NIH Clinical Center; M. Centola, PhD, Oklahoma Medical Research Foundation, and Haus Bioceuticals Inc.; F.W. Miller, MD, PhD, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH; L.G. Rider, MD, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH. Address correspondence to Dr. L.G. Rider, Deputy Chief, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH, Building 10, CRC Rm 6-5700, MSC 1301, 10 Center Drive, Bethesda, Maryland 20892-1301, USA. E-mail: riderl@mail.nih.gov. Accepted for publication July 19, 2019.
Michael Centola
From the Environmental Autoimmunity Group, Clinical Research Branch, US National Institute of Environmental Health Sciences, National Institutes of Health (NIH); Coagulation Laboratory, NIH Clinical Center; Laboratories of Molecular Biology and Pathology, National Cancer Institute, NIH, Bethesda, Maryland; Oklahoma Medical Research Foundation; Haus Bioceuticals Inc., Oklahoma City, Oklahoma, USA. This work was supported in part by the Intramural Research Program of the National Institute of Environmental Health Sciences (project ES101074, Takayuki Kishi, Lisa Rider, and Frederick Miller). Takayuki Kishi was supported by a research fellowship of the Cure JM Foundation and by Tokyo Women’s Medical University. T. Kishi, MD, PhD, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH; J. Chipman, MS, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH; M. Evereklian, MSN, CPNP-BC, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH; K. Nghiem, MS, Coagulation Laboratory, NIH Clinical Center; M. Stetler-Stevenson, MD, Laboratories of Molecular Biology and Pathology, National Cancer Institute, NIH; M.E. Rick, MD, Coagulation Laboratory, NIH Clinical Center; M. Centola, PhD, Oklahoma Medical Research Foundation, and Haus Bioceuticals Inc.; F.W. Miller, MD, PhD, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH; L.G. Rider, MD, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH. Address correspondence to Dr. L.G. Rider, Deputy Chief, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH, Building 10, CRC Rm 6-5700, MSC 1301, 10 Center Drive, Bethesda, Maryland 20892-1301, USA. E-mail: riderl@mail.nih.gov. Accepted for publication July 19, 2019.
Frederick W. Miller
From the Environmental Autoimmunity Group, Clinical Research Branch, US National Institute of Environmental Health Sciences, National Institutes of Health (NIH); Coagulation Laboratory, NIH Clinical Center; Laboratories of Molecular Biology and Pathology, National Cancer Institute, NIH, Bethesda, Maryland; Oklahoma Medical Research Foundation; Haus Bioceuticals Inc., Oklahoma City, Oklahoma, USA. This work was supported in part by the Intramural Research Program of the National Institute of Environmental Health Sciences (project ES101074, Takayuki Kishi, Lisa Rider, and Frederick Miller). Takayuki Kishi was supported by a research fellowship of the Cure JM Foundation and by Tokyo Women’s Medical University. T. Kishi, MD, PhD, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH; J. Chipman, MS, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH; M. Evereklian, MSN, CPNP-BC, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH; K. Nghiem, MS, Coagulation Laboratory, NIH Clinical Center; M. Stetler-Stevenson, MD, Laboratories of Molecular Biology and Pathology, National Cancer Institute, NIH; M.E. Rick, MD, Coagulation Laboratory, NIH Clinical Center; M. Centola, PhD, Oklahoma Medical Research Foundation, and Haus Bioceuticals Inc.; F.W. Miller, MD, PhD, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH; L.G. Rider, MD, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH. Address correspondence to Dr. L.G. Rider, Deputy Chief, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH, Building 10, CRC Rm 6-5700, MSC 1301, 10 Center Drive, Bethesda, Maryland 20892-1301, USA. E-mail: riderl@mail.nih.gov. Accepted for publication July 19, 2019.
Lisa G. Rider
From the Environmental Autoimmunity Group, Clinical Research Branch, US National Institute of Environmental Health Sciences, National Institutes of Health (NIH); Coagulation Laboratory, NIH Clinical Center; Laboratories of Molecular Biology and Pathology, National Cancer Institute, NIH, Bethesda, Maryland; Oklahoma Medical Research Foundation; Haus Bioceuticals Inc., Oklahoma City, Oklahoma, USA. This work was supported in part by the Intramural Research Program of the National Institute of Environmental Health Sciences (project ES101074, Takayuki Kishi, Lisa Rider, and Frederick Miller). Takayuki Kishi was supported by a research fellowship of the Cure JM Foundation and by Tokyo Women’s Medical University. T. Kishi, MD, PhD, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH; J. Chipman, MS, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH; M. Evereklian, MSN, CPNP-BC, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH; K. Nghiem, MS, Coagulation Laboratory, NIH Clinical Center; M. Stetler-Stevenson, MD, Laboratories of Molecular Biology and Pathology, National Cancer Institute, NIH; M.E. Rick, MD, Coagulation Laboratory, NIH Clinical Center; M. Centola, PhD, Oklahoma Medical Research Foundation, and Haus Bioceuticals Inc.; F.W. Miller, MD, PhD, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH; L.G. Rider, MD, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH. Address correspondence to Dr. L.G. Rider, Deputy Chief, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH, Building 10, CRC Rm 6-5700, MSC 1301, 10 Center Drive, Bethesda, Maryland 20892-1301, USA. E-mail: riderl@mail.nih.gov. Accepted for publication July 19, 2019.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Endothelial Activation Markers as Disease Activity and Damage Measures in Juvenile Dermatomyositis
Takayuki Kishi, Jonathan Chipman, Melvina Evereklian, Khanh Nghiem, Maryalice Stetler-Stevenson, Margaret E. Rick, Michael Centola, Frederick W. Miller, Lisa G. Rider
The Journal of Rheumatology Aug 2019, jrheum.181275; DOI: 10.3899/jrheum.181275
Endothelial Activation Markers as Disease Activity and Damage Measures in Juvenile Dermatomyositis
Takayuki Kishi, Jonathan Chipman, Melvina Evereklian, Khanh Nghiem, Maryalice Stetler-Stevenson, Margaret E. Rick, Michael Centola, Frederick W. Miller, Lisa G. Rider
The Journal of Rheumatology Aug 2019, jrheum.181275; DOI: 10.3899/jrheum.181275